Published in J Biomed Sci on January 07, 2015
New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46
The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene (2007) 10.08
Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif (2003) 4.68
Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol (2002) 4.50
Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J Cell Biol (2001) 4.38
Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol (1995) 4.26
Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J (1991) 4.04
Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer (2010) 3.74
AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell (2003) 3.50
The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol (1999) 3.15
Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A (1995) 3.13
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res (2002) 2.55
Microtubule-targeted anticancer agents and apoptosis. Oncogene (2003) 2.49
Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol (2007) 2.36
Aurora-B phosphorylates Histone H3 at serine28 with regard to the mitotic chromosome condensation. Genes Cells (2002) 2.28
New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta (2011) 2.22
The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene (2000) 2.15
Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res (1998) 1.99
Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res (2004) 1.83
Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ (2002) 1.72
Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer (1999) 1.70
Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res (1996) 1.48
Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf (2007) 1.46
Aurora A, mitotic entry, and spindle bipolarity. Proc Natl Acad Sci U S A (2006) 1.46
Aurora-A kinase is essential for bipolar spindle formation and early development. Mol Cell Biol (2008) 1.44
VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle (2007) 1.41
Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res (2002) 1.40
Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res (2010) 1.36
Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat (2007) 1.35
Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res (2006) 1.31
Bcl-2 family interaction with the mitochondrial morphogenesis machinery. Cell Death Differ (2010) 1.31
Paclitaxel in cancer therapy. Expert Opin Pharmacother (2002) 1.26
Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol (2009) 1.18
Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis (2006) 1.16
Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents. Biochem Biophys Res Commun (2006) 1.11
Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. Drug Metab Dispos (2011) 1.04
Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate. Neoplasia (2007) 0.91
Overexpression of active Aurora-C kinase results in cell transformation and tumour formation. PLoS One (2011) 0.90
Cytoskeleton targeting value in prostate cancer treatment. Am J Clin Exp Urol (2014) 0.90
Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest (2011) 0.88
Synchronised phosphorylation of BNIP3, Bcl-2 and Bcl-xL in response to microtubule-active drugs is JNK-independent and requires a mitotic kinase. Biochem Pharmacol (2010) 0.86
The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol (2003) 0.86
Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol (1998) 0.85
Potential antitumor agents. 37. Synthesis and antitumor activity of guanylhydrazones from imidazo[2,1-b]thiazoles and from the new heterocyclic system thiazolo[2',3':2,3]imidazo[4,5-c]quinoline. J Med Chem (2005) 0.84
Interaction of pseudolaric acid B with the colchicine site of tubulin. Biochem Pharmacol (2012) 0.81
PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors. Biochem Pharmacol (2014) 0.81
CIL-102 induces matrix metalloproteinase-2 (MMP-2)/MMP-9 down-regulation via simultaneous suppression of genetic transcription and mRNA stability. Int J Biochem Cell Biol (2012) 0.79
2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase. Br J Pharmacol (2010) 0.79
Substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and analogues: synthesis, cytotoxic activity, and study of the mechanism of action. J Med Chem (2012) 0.77
2-(1H-Imidazol-1-yl)-4-[3-(trifluoro-meth-yl)phen-yl]-1,3-thia-zole. Acta Crystallogr Sect E Struct Rep Online (2013) 0.76